Honors
Our APIs have successfully completed U.S. FDA Drug Master File (DMF) filings:

Tirzepatide API (DMF #041036) – Filed in January 2025

Semaglutide API (DMF #041860) – Filed in June 2025

We have obtained the Pharmaceutical Production License.

Certified to ISO 9001 Quality Management System standards.

4 invention patents have been authorized, and 18 new invention patents are being declared
  • 1. A Solid-Phase Synthesis Method of Insulin (Patent No.: CN 106432472 B)
  • 2. A Solid-Phase Synthesis Method of Semaglutide (Patent No.: CN 106478806 B)
  • 3. 3)A Method for the Specific Synthesis of Histamine-Related Peptides (Patent No.: CN 106519008 B)
  • 4. 4)Application of 1-Hydroxy-1,2,3-Benzotriazine-4(3H)-One in Peptide Synthesis (Patent No.: CN 103864885 B)

11 utility model patents have been authorized, and 5 new utility model patents are being declared

*Note: The ownership of the original patents has been transferred to our company.